As the US experience reveals, getting agreement in one country is hard enough. Getting 27 member countries to agree is maddening.
Aside from the chaos of competing health regimens, philosophies and budgets, the EU hoped for a European vaccine, which has yet to materialize and its investment in the AstraZeneca model created problems due, in part, to Brexit. The Union was also cautious about how much money to invest and was late to agreements with those companies that were clearly leaders even though it could be argued the Pfizer/BioNTech vaccine was primarily European. Such small-minded regional thinking is dangerous when facing a global problem. JL
Lauren Chadwick reports in EuroNews:
The European Union was slower to approve the first coronavirus vaccines than the UK and the US. The European regulator requires input from every member state (and) under the EU process, the drugmaker will be held liable if anything with the vaccine goes wrong. (Plus) "We wanted to invest in a diversified portfolio of different companies
using different technologies because we were not sure which vaccine
would be successful. The right thing to do was to throw money at the problem and make
sure that we got enough of the vaccines that were actually useable in
the time frame that they were needed. And that wasn’t done,"